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Summary
In the mantle cell lymphoma (M CL)-002 study, lenalidomide demonstrated 
significantly improved median progression-free survival (PFS) compared 
with investigator’s choice (IC) in patients with relapsed/refractory MCL. 
Here we present the long-term follow-up data and results of preplanned 
subgroup exploratory analyses from MCL-002 to evaluate the potential 
im pact o f demographic factors, baseline clinical characteristics and prior 
therapies on PFS. In MCL-002, patients with relapsed/refractory M CL were 
randomized 2:1 to receive lenalidomide (25 m g/day orally on days 1-21; 
28-day cycles) or single-agent IC therapy (rituximab, gemcitabine, fludara- 
bine, chlorambucil or cytarabine). The intent-to-treat population com ­
prised 254 patients (lenalidomide, n =  170; IC, n =  84). Subgroup analyses 
of PFS favoured lenalidomide over IC across m ost characteristics, including 
risk factors, such as high M CL International Prognostic Index score, age 
>65 years, high lactate dehydrogenase (LDH), stage III/IV disease, high 
tum our burden, and refractoriness to last prior therapy. By multivariate 
Cox regression analysis, factors associated with significantly longer PFS 
(other than lenalidomide treatment) included normal LDH levels 
(P <  0-001), nonbulky disease (P =  0-045), <3 prior antilymphoma treat­
ments (P =  0-005), and >6 months since last prior treatment (P =  0-032). 
Overall, lenalidomide improved PFS versus single-agent IC therapy in 
patients with relapsed/refractory MCL, irrespective of many demographic 
factors, disease characteristics and prior treatment history.
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Mantle cell lym phom a (M CL) accounts for ~6%  o f  all cases 
o f  non-Hodgkin lym phom a (N H L) and typically presents as 
advanced stage disease in patients over 60 years o f  age (Avivi 
& Goy, 2015). First-line dose-intensive chemoimmunother- 
apy, with or without stem  cell transplantation, leads 
im proved progression-free survival (PFS) in younger patients 
with M CL and an overall fit status (Dreyling et al, 2014). 
Older patients with m ultiple comorbidities are usually treated 
with less aggressive regimens. M CL typically relapses and 
becomes increasingly m ore challenging to m anage over the 
course o f  the disease. With current therapies in the relapsed/ 
refractory setting (bortezomib, tem sirolim us, lenalidomide, 
ibrutinib), median overall survival (OS) following relapse is 
approxim ately 2 years (Avivi & Goy, 2015). While multiple 
treatment options are available, som e with proven benefit in 
random ized trials (e.g., lenalidomide, ibrutinib), their role in 
the standard o f  care for relapsed/refractory disease and the 
best possible treatment sequence remains to be defined 
(Dreyling et a l, 2014; Avivi & Goy, 2015).
Lenalidom ide is an oral im m unom odulatory drug 
(IMiD®) with direct and im m une-m ediated m echanisms o f  
action (Gribben et al, 2015) and has shown clinical activity 
and safety in multiple studies, including 2 single-arm, phase 
II trials (NHL-002 and NHL-003) in heavily pretreated 
patients with relapsed/refractory aggressive NHL, including 
M CL (Haberm ann et al, 2009; Zinzani et al, 2013). Subse­
quently in the single-arm, phase II MCL-001 (EMERGE) 
study in 134 patients with M CL who had relapsed during 
treatment with, or developed disease refractory to, borte- 
zomib, lenalidomide treatment resulted in  an overall 
response rate (ORR) o f  28%, with a m edian response dura­
tion o f  16-6 m onths (Goy et al, 2013, 2015). M ore recently, 
in the randomized, open-label, multicentre, phase II MCL- 
002 (SPRINT) study, the lenalidomide arm  showed a statisti­
cally significant and clinically m eaningful im provem ent in 
the prim ary endpoint o f  PFS com pared with investigator’s 
choice (IC) o f  single-agent therapy (rituximab, gemcitabine, 
fludarabine, chloram bucil or cytarabine), with a manageable 
safety profile (Trneny et a l , 2016). This prim ary analysis o f  
M CL-002, which had a cut-off date o f  7 March 2014 and a 
m edian follow-up o f  15-9 m onths for the overall study
population, found a m edian PFS o f  8-7 m onths for lenalido­
m ide versus 5-2 months for IC (hazard ratio [HR] 0-61, 95% 
confidence interval [CI] 0-44-0-84; P =  0-004). Per the study 
protocol, follow-up to M CL-002 continues until the death o f  
70% o f  patients, m edian follow-up o f  responding patients is 
greater than 2 years, m edian duration o f  response has been 
reached, or 4 years have passed from  last patient random iza­
tion, whichever comes later.
In the present report, we provide long-term follow-up 
data and results o f  preplanned subgroup exploratory analyses 
from  the M CL-002 study to evaluate the potential im pact o f  
dem ographic factors, baseline clinical characteristics, and 
prior therapies on PFS in patients with relapsed/refractory 
M CL random ized to receive lenalidomide versus IC.
Patients and methods
Study design
The m ethodology for M CL-002 (ClinicalTrials.gov identifier, 
N CT00875667) has been previously described (Trneny et al, 
2016). Key inclusion criteria were m inim um  age 18 years, 
Eastern Cooperative Oncology Group (ECOG) performance 
status (PS) o f  0-2, histologically confirmed M CL with cyclin 
D1 overexpression by imm unohistochem istry, measurable 
disease >2  cm  in the longest diameter, refractory to prior 
therapy or <3 relapses and had docum ented progressive dis­
ease after >1 prior com bination chemotherapy regimen with 
an alkylating agent and an anthracycline, cytarabine and/or 
fludarabine (with or without rituxim ab); and ineligibility for 
intensive chemotherapy or stem  cell transplantation (SCT). 
Patients were stratified by time from  diagnosis (<3 vs. 
>3 years), time from  last antilym phom a therapy (<6 vs. 
>6  m onths), and prior autologous SC T and random ized 2:1 
to lenalidomide or IC. Oral lenalidomide was initiated at 
25 mg/day, days 1-21 o f  each 28-day cycle until progressive 
disease (PD) or as tolerated. Rituxim ab and chlorambucil 
were adm inistered until PD or unacceptable toxicity, whereas 
gemcitabine, fludarabine and cytarabine were given for <6 
cycles. Patients random ized to IC  were allowed to cross over 
to lenalidomide following docum ented PD.
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All patients provided written inform ed consent prior to 
study initiation. The study protocol and its amendm ents 
were approved by an institutional review board or indepen­
dent ethics committee, or centrally i f  required by national 
regulations, and were conducted in accordance with the ethi­
cal principles o f  the Declaration o f  Helsinki and in com pli­
ance with Good Clinical Practice.
Post hoc assessments
As prospectively outlined in the study protocol, planned 
analyses for longer follow-up were perform ed by investigator 
assessm ent to evaluate PFS in the overall study population 
and for prespecified subgroups at baseline (i.e., the time o f 
random ization unless otherwise stated). These subgroups are 
grouped in 3 categories based on their association with M CL 
International Prognostic Index (M IPI) score, other patient 
characteristics and treatment history. Specific parameters and 
cut-off/com parison values within each subgroup are defined 
in  Supplementary Table SI.
We evaluated PFS in the intent-to-treat (ITT) population, 
which included all randomized patients irrespective o f  receipt 
o f  study treatment. Com puted tom ography (CT) scans (or 
m agnetic resonance im aging i f  CT was contraindicated) were 
perform ed every 2 cycles ( ± 7  days) for 6 m onths and then 
every 90 days (± 1 5  days) until documented PD or death.
Statistical analyses
PFS was characterized by Kaplan-M eier estimates with P  val­
ues per log-rank test with determ ination o f  m edian values 
and 95%  CIs. Univariate and m ultivariate Cox regression 
m odels evaluated whether baseline subgroup factors were 
predictive o f  the risk o f  progression or death. Variables with 
a P  value <0-20 by univariate analysis were selected for m u l­
tivariate analysis. Final variables were selected using a step­
wise selection m ethod with entry level P =  0-20 and stay 
level P =  0-15. ORR was defined according to Cheson et al 
(1999) and statistical significance determined by W ald X 2 
test (P  <  0-05).
Results
Patient demographics and disposition
The ITT population com prised 254 patients (n =  170 
lenalidomide; n  =  84 IC) enrolled between April 2009 and 
M arch 2013. Three patients random ized to lenalidomide and 
1 patient randomized to IC  did not receive study treatment. 
Overall, patients had a m edian age o f  68-5 years, 68% were 
65 years or older, and 73% were male. Patients had received 
a m edian o f  2 (range, 1-5) prior treatment regimens, o f 
which 19% had received prior SCT. As previously reported, 
the treatment arms were balanced in  baseline characteristics 
except for high-risk MIPI score, high tum our burden, bulky
disease, and high lactate dehydrogenase (LDH ) concentra­
tion, which were m ore prevalent am ong patients randomized 
to lenalidomide versus IC  (Trneny et al, 2016). Also, com ­
pared with the IC treatment arm, m ore patients in the 
lenalidomide arm  had received a higher number o f  previous 
anti-lymphom a treatments and had been refractory to their 
last previous therapy.
As o f  the data cut-off o f  7 March 2016, 163 o f  250 
patients (65% ) overall who received treatment had died. 
While on study, only 17 (7% ) patients had died during or 
within 30 days o f  their study treatment (lenalidomide or IC). 
Causes o f  death were similar in both treatment groups, pri­
m arily due to m alignant lym phoma (46%  lenalidomide vs. 
45%  IC), other/unknown causes (17%  lenalidomide vs. 20% 
IC) and toxicity (1 lenalidomide patient vs. 2 IC  patients). 
Sixteen patients were ongoing on initial lenalidomide treat­
ment and 1 patient in the IC (rituxim ab) group. Addition­
ally, 5 o f  40 patients who crossed over from  IC to 
lenalidomide were still receiving lenalidomide treatment.
Progression-free survival
The m edian follow-up for all surviving patients was 
41- 3 m onths, which was an additional 20 m onths from  the 
initial assessment and published report (Trneny et al, 2016). 
Lenalidom ide continued to show longer m edian PFS than IC 
(8-6 vs. 5-4 m onths, respectively; P =  0-006; Fig 1A). An 
im provem ent in PFS with lenalidomide over IC was evident 
across m ost baseline subgroups, particularly those with 
higher numbers o f  patients, and including patients aged 
>65 years (P  =  0-001; Fig 1B); with advanced stage III/IV 
disease at diagnosis (P  =  0-014; Fig 1C), high LDH 
(P =  0-016; Fig 1D), high tum our burden (P =  0-007; 
Fig 1E), bulky disease (P =  0-068; Fig 1F); and whose disease 
was refractory to their last therapy (P <  0-001; Fig 1G). In 
support o f  higher PFS in these sam e categories, lenalidomide 
treatment showed higher ORR com pared with IC at the ear­
liest efficacy assessm ent (Cycle 3) when treatment on all IC 
com parators was still ongoing (Supplementary Figure S1).
Figure 2 lists the total number o f  patients per arm  and 
subgroup depicted in the forest plots, along with their associ­
ated m edian PFS values and P  value. Subgroup data were 
m issing for som e patients. Subgroups that had statistically 
significant improvements in PFS favouring lenalidomide over 
IC included patients with intermediate (P  =  0-033) and high 
MIPI score at baseline (P =  0-037), age >65 years 
(P =  0-001), ECOG PS 0-1 (P =  0-025) or 2 -4  (P =  0-019), 
norm al (P =  0-049) or high LDH (P =  0-016), and 
<6-7 x  109/l white blood cell (W BC) counts (P =  0-011) 
(Fig 2A). The analysis o f  other patient and disease character­
istics (Fig 2B) showed statistically significant improvements 
in PFS favouring lenalidomide in females (P =  0-035), stage 
III/IV disease at diagnosis (P =  0-014) irrespective o f  tum our 
burden (low P =  0-018; high P =  0-007), in patients without 
bulky disease (P =  0-004) or bone m arrow involvement
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(A)
Number at risk  
Lenalidomide  
Control
Number at risk  
Lenalidom ide 115 
Control 57
Number at r isk  
Lenalidom ide 153 
Control 79
Months from  randomization
All Patients
Fig 1. Kaplan-Meier curves of PFS in the 
lenalidomide versus IC treatment arms for all 
patients (A) and for patient subgroups with 
age >65 years (B), advanced MCL stage III/IV 
at diagnosis (C), high LDH at baseline (D), 
high tumour burden at baseline (E), bulky dis­
ease at baseline (F) and disease refractory to 
last treatment (G). 95% CI, 95% confidence 
interval; HR, hazard ratio; IC, investigator’s 
choice; LDH, lactate dehydrogenase; MCL, 
mantle cell lymphoma; PFS, progression-free 
survival.
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(G) Refractory patients
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Control 25 4 0 Fig 1. Cotinued.
(P  =  0-006) and in patients with both norm al (P  =  0-026) 
and m oderate renal function (P  =  0-019).
We also evaluated subgroups to examine the potential 
im pact o f  prior therapy on PFS outcom es. As shown in 
Fig 2C, lenalidomide significantly im proved PFS com pared 
with IC  in patients who were <3 years from  M CL
228
diagnosis (P  =  0-002); had m ore prior systemic antilym­
phom a therapies (P  =  0-002 for >2; P  =  0-020 for >3); 
were refractory to their last therapy (P <  0-001); had >1
prior relapses (P =  0-007 for >1, P =  0-007 for >2,
P =  0-006 for <3); regardless o f  time from  last prior ther­
apy (P =  0-042 for <6  months, and P =  0-033 for
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diagnosis
Low
Intermed-
41/61
37/51
27/35
17/22
75
8 4
57
6
0 035
0 255
High 36/40 12/14 5 7 2 1 0 ■ 549
Low 28/42 15/21 16-4 5 7 0 ■ 159
MIPI score at 
baseline Intermed- 46/66 27/37 121 6 4 0 033
High 52/60 23/25 3 7 21 0 037
Age
<65 years 
>65 years ■-
41/55
86/115
21/27
45/57
5 7
107
6 8 
4 3
0 637 
0 001
ECOG PS
0-1
2
* 107/142
20/27
55/73
11/11
8 6
90
5 9
19
0 025 
0019
Low ■ 0/2 2/2 NA 4 6 0 ■ 157
LDH Normal 67/94 35/51 12-2 78 0 049
High + - 59/73 28/30 3 8 2 0 0016
<67 ■ m - 55/79 37/46 81 4 4 0011
WBC 6-7-<10 42/56 20/27 11 5 7 4 0 085
(x109/l) 10-<15 — i ------- 15/19 5/7 8 4 8 4 0 804
>15 14/15 4/4 2 9 3 9 0 731
I----------- ------------- 1-----------1------------1--------1
0 1 2 3 4 5
HR (95% CI)
(B) Median PFS,
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Sex Male
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Fig 2. Forest plots of treatment effects on median PFS by subgroups according to MIPI-based characteristics (A), other patient characteristics 
(B), and prior treatment history (C). Improved PFS to the left of the vertical line (i.e., at 1) favours lenalidomide and to the right of the line 
favours IC. Black squares represent the HR; horizontal lines lines represent 95% CI. Statistically significant (P <  0-05) values and the specified fac­
tors are shown in bold. 95% CI, 95% confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; 
IC, investigator’s choice; Intermed., intermediate; LDH, lactate dehydrogenase; Len, l lenalidomide; MCL, mantle cell lymphoma; MIPI, MCL 
International Prognostic Index; PFS, progression-free survival; SCT, stem cell transplantation; WBC, white blood cell count.
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Fig 2. Continued.
> 6  m onths); received prior rituximab- (P =  0-014) or flu- 
darabine-containing therapy (P =  0-038); and had not 
received prior high-dose therapy (HDT; P  =  0-003) or 
undergone prior SCT (P =  0-003). Despite the lim itation
of small patient num bers in som e subgroups, these data 
suggest that lenalidomide m ay significantly im prove PFS 
com pared with IC  treatment irrespective o f  ECOG status, 
high LD H  and tum our burden.
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Univariate and multivariate analyses for progression-free 
survival
Further evaluation o f  subgroups by univariate Cox regression 
analysis showed that treatment group (lenalidom ide favoured 
over IC) was the m ain effect associated with significantly 
im proved PFS (H R  =  0-65; P =  0-005), which was also highly 
significant by multivariate analysis (H R  =  0-42; P <  0-001) 
(Table I). Other subgroups with statistically significant 
improvements in PFS (P <  0-05) in the univariate analysis
were low/intermediate MIPI score at diagnosis and baseline, 
norm al LDH levels, <10 x  109/l W BC counts, norm al renal 
function, <3 prior systemic antilym phom a therapies and 
>6  m onths since last prior therapy.
In the multivariate Cox regression analysis, norm al LDH 
level was associated with highly significant improvem ent in 
PFS (P <  0-001) with lenalidomide treatment versus IC 
(Table I). Other factors retaining significance in the m ulti­
variate m odel included no bulky disease (P  =  0-045), <3
Table I. Univariate and multivariate analyses by Cox Regression on PFS by investigator assessment.*
Baseline variable
Univariate analysis 
HR (95% CI) P value
Multivariate analysis 
HR (95% CI) P value
Treatment (lenalidomide versus IC) 0-65 (0-48-0-87) 0-005 0-42 (0-28-0-62) <0-001
MIPI-based characteristics
MIPI score at diagnosis (high versus low/intermediate) f 1-57 (1-12-2-20) 0-009 — —
MIPI score at baseline (high versus low/intermediate) f 2-11 (1-57-2-83) <0-001 1-51 (1-00-2-27) 0-052
Age, years (>65 vs. <65) 1-02 (0-75-1-38) 0-919 — —
ECOG PS (2 vs. 0-1) 1-46 (0-99-2-16) 0-053 — —
LDH (high versus low/normal)} 2-00 (1-49-2-67) <0-001 2-02 (1-35-3-01) <0-001
WBC (>10 x  109/l vs. <10 x  109/l) 1-55 (1-08-2-21) 0-017 — —
Other patient characteristics
Sex (female versus male) 0-86 (0-62-1-18) 0-348 — —
MCL stage at diagnosis (III/IV versus I/II) 0-81 (0-46-1-42) 0-461 — —
Tumour burden (low versus high) § 0-81 (0-60-1-08) 0-155 — —
Bulky disease (yes versus no)^ 1-40 (0-98-2-01) 0-063 1-57 (1-01-2-43) 0-045
Bone marrow assessment (negative versus indeterminate/positive)** 0-72 (0-44-1-20) 0-206 — —
Renal function (normal versus moderate/severe insufficiency)ff 0-60 (0-43-0-84) 0-003 — —
Prior treatment history
Time from MCL diagnosis to first dose (>3 versus <3 years) 0-85 (0-64-1-14) 0-280 — —
Number of prior systemic antilymphoma therapies (>3 versus <3) 1-51 (1-11-2-06) 0-009 1-75 (1-19-2-58) 0-005
Disease status to last prior therapy (relapsed}} versus refractory) 0-77 (0-58-1-03) 0-075 — —
Time from last prior therapy to first dose (>6 vs. <6 months) 0-74 (0-55-0-98) 0-034 0-68 (0-47-0-97) 0-032
Time since last rituximab to first dose (>230 vs. <230 days) 0-79 (0-59-1-07) 0-127 — —
Prior HDT (yes versus no)§§ 0-98 (0-68-1-42) 0-930 — —
Prior SCT (yes versus no) 0-96 (0-66-1-39) 0-837 — —
95% CI, 95% confidence interval; CR, complete response; CrCl, creatinine clearance; ECOG PS, Eastern Cooperative Oncology Group perfor­
mance status; HDT, high-dose therapy; HR, hazard ratio; LDH, lactate dehydrogenase; MCL, mantle cell lymphoma; MIPI, MCL International 
Prognostic Index; PFS, progression-free survival; SCT, stem cell transplantation; WBC, white blood cell count.
*Variables with P value <0 20 in the univariate analysis were selected for multivariate analysis. Final variables were selected using a stepwise selec­
tion method with entry level = 0 20 and stay level = 015. Multivariate survival analysis using Cox’s regression model was estimated using 162 
patients.
fMIPI score = 0 03535 *  age + 0-6978 *  (if ECOG PS >1) + 1-367 *  log10 (LDH/upper limit of normal) + 0-9393 *  log10 (WBC per 10~6/l). 
}High LDH was >3-4 pkat/l for patients aged <60 years and >3-5 pkat/l for those aged >60 years; low LDH was <1-8 pkat/l; normal was defined 
per local laboratory criteria.
§High tumour burden was defined by at least one lesion >5 cm in diameter or three lesions >3 cm in diameter by central radiology review. 
^Bulky disease was defined by at least one lesion >7 cm in the longest diameter by central radiology review.
**For estimation of bone marrow involvement by local pathologist, negative was defined as having no aggregates or only a few well-circumscribed 
lymphoid aggregates, indeterminate bone marrow was defined as having an increased number/size of lymphoid aggregates without overt malig­
nancy, and positive was defined as an unequivocal malignancy.
f f  Normal renal function was defined as CrCl of >60 ml/min; moderate insufficiency had CrCl >30 to <60 ml/min but not requiring dialysis; sev­
ere insufficiency had CrCl <30 ml/min. 2 patients had severe insufficiency in this study.
}}Relapse included patients with best response to last treatment of CR, unconfirmed CR, or partial response.
§§HDT was defined as SCT, hyper-CVAD (hyper fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone plus methotrexate and 
cytarabine), or R-hyper-CVAD (rituximab + Hyper CVAD).
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Fig 3. Kaplan-Meier curves of overall survival 
in the lenalidomide versus IC treatment arms 
for all patients. 95% CI, 95% confidence inter­
val; HR, hazard ratio; IC, investigator’s choice; 
OS, overall survival.
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prior antilym phom a treatments (P =  0-005) and >6  m onths 
since last prior therapy (P =  0-032).
Univariate and multivariate analyses for overall survival
M edian OS was 27-8 m onths (95%  CI, 22-6-35-3) for 
lenalidomide versus 21-2 m onths (95%  CI, 16-0-31-7) for IC 
(H R  =  0-86; 95%  CI, 0-62-1-18; Mantel-Byar P  =  0-34 
[taking into account the effect o f  crossover]; Fig 3). We also 
perform ed univariate and multivariate analyses for OS as a 
way o f  identifying and/or confirming the role o f  potential 
independent factors on survival (Table II). For OS, although 
the com parison between treatment groups (lenalidom ide ver­
sus IC) did not achieve statistical significance, baseline factors 
that were statistically significant in the univariate analysis 
(P <  0-05) and led to im proved OS were ECOG PS 0-1, nor­
m al LDH, low/intermediate MIPI score at diagnosis or base­
line, <3 prior antilym phom a therapies, relapsed status to last 
therapy, >6  m onths from  last prior therapy, low tum our bur­
den and no bulky disease. Multivariate analysis o f  OS identi­
fied female sex as a signficiant independent prognostic factor 
(H R  =  0-54; 95%  CI, 0-33-0-89; P  =  0-015).
Discussion
The prim ary analysis o f  M CL-002 dem onstrated that 
lenalidomide significantly im proved PFS com pared with sin­
gle-agent IC  therapy in patients with relapsed/refractory 
M CL, resulting in a significant risk reduction in PD or death 
(Trneny et a l, 2016). The current exploratory subgroup and 
m ultivariate analyses extend these findings by uncovering an 
im proved clinical benefit with lenalidomide com pared with 
IC in patients with a wide range o f  dem ographic and base­
line clinical characteristics. Moreover, the PFS benefit o f 
lenalidomide over IC does not appear to be affected by the 
level o f  disease activity (measured by increased LDH ), m ore 
advanced stage M CL or tum our burden. Additionally, 
lenalidomide treatment showed an early significant
improvem ent in ORR com pared with IC at cycle 3, support­
ing later differences in PFS. The PFS advantage o f  lenalido- 
mide in patients with poor prognosis (high MIPI score at 
baseline) and the elderly, who represent the m ajority o f 
patients with relapsed/refractory MCL, is o f  particular clinical 
relevance.
Previous subgroup analyses for lenalidomide were con­
ducted in the MCL-001 study, which evaluated lenalidomide 
in 134 M CL patients who had experienced relapse after 
bortezomib or whose disease was refractory to the drug (Goy 
et al, 2013). Because MCL-001 did not have a control arm, 
the subgroup analyses evaluated the im pact o f  baseline fac­
tors on ORR and duration o f  response (prim ary study end­
points). Lenalidom ide treatment effects were consistent 
across subgroups in M CL-001, with high LDH identified as 
the only significant factor for lower activity in the univariate 
and multivariate analyses (G oy et al, 2013).
The present M CL-002 subgroup analyses confirm these 
findings in a randomized, controlled setting. High LDH is a 
known adverse prognostic factor in M CL (Hoster et al,
2014) and was identified in the current multivariate analysis 
as an independent factor for worse PFS. Notably, lenalido- 
mide showed a significant improvem ent in PFS com pared 
with IC in patients with high LDH. Similarly, lenalidomide 
exhibited a statistically significant PFS benefit in other high- 
risk subgroups, including patients with high baseline MIPI 
score, older age (>65 years), stage III/IV disease, high 
tum our burden and refractoriness to last prior therapy. 
Lenalidom ide treatment was also associated with a non-sta- 
tistically significant trend toward longer m edian PFS in sev­
eral other higher-risk subgroups, including those with bulky 
disease (>7 cm) and in those who received prior H D T and/ 
or SCT.
The M CL-002 study was prospectively conducted in a 
large number o f  patients across multiple centres to examine 
PFS and was the first randomized, controlled trial o f 
lenalidomide in patients with relapsed/refractory M CL. The 
present subgroup analyses were prespecified for analysis per
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Table II. Univariate and multivariate analyses by Cox Regression on overall survival by investigator assessment.*
Baseline variable
Univariate analysis 
HR (95% CI) P value
Multivariate analysis 
HR (95% CI) P value
Treatment (lenalidomide versus IC) 0-86 (0-62-1-18) 0-35 — —
MIPI-based characteristics
MIPI score at diagnosis (high versus low/intermediate) f 1-80 (1-27-2-56) 0-001 — —
MIPI score at baseline (high versus low/intermediate) f 2-00 (1-47-2-74) <0-001 1-49 (0-96-2-32) 0-08
Age, years (>65 vs. <65) 1-14 (0-82-1-60) 0-44 — —
ECOG PS (2 vs. 0-1) 1-62 (1-07-2-43) 0-02 — —
LDH (high versus low/normal) } 1-96 (1-44-2-68) <0-001 1-50 (0-97-2-30) 0-07
WBC (>10 x  109/l vs. <10 x  109/l) 1-42 (0-96-2-08) 0-08 — —
Other patient characteristics
Sex (female versus male) 0-77 (0-54-1-11) 0-16 0-54 (0-33-0-89) 0-02
MCL stage at diagnosis (III/IV versus I/II) 0-96 (0-50-1-82) 0-89 — —
Tumour burden (low versus high) § 0-68 (0-50-0-94) 0-02 — —
Bulky disease (yes versus no)f| 1-55 (1-06-2-25) 0-02 1-54 (0-97-2-44) 0-07
Bone marrow assessment (negative versus indeterminate/positive)** 0-71 (0-42-1-22) 0-22 — —
Renal function (normal versus moderate/severe insufficiency)ff 0-71 (0-50-1-01) 0-06 — —
Prior treatment history
Time from MCL diagnosis to first dose (>3 vs. <3 years) 0-82 (0-60-1-12) 0-22 — —
Number of prior systemic antilymphoma therapies (>3 vs. <3) 1-59 (1-14-2-22) 0-006 1-49 (0-98-2-25) 0-06
Disease status to last prior therapy (relapsed}} versus refractory) 0-70 (0-51-0-96) 0-03 — —
Time from last prior therapy to first dose (>6 vs. <6 months) 0-60 (0-44-0-82) 0-001 0-69 (0-47-1-04) 0-08
Time since last rituximab to first dose (>230 vs. <230 days) 0-74 (0-53-1-02) 0-07 — —
Prior HDT (yes versus no)§§ 1-13 (0-77-1-68) 0-53 — —
Prior SCT (yes versus no) 1-09 (0-74-1-62) 0-66 — —
95% CI, 95% confidence interval; CR, complete response; CrCl, creatinine clearance; ECOG PS, Eastern Cooperative Oncology Group perfor­
mance status; HDT, high-dose therapy; HR, hazard ratio; LDH, lactate dehydrogenase; MCL, mantle cell lymphoma; MIPI, MCL International 
Prognostic Index; PFS, progression-free survival; SCT, stem cell transplantation; WBC, white blood cell count.
^Variables with P value <0-20 in the univariate analysis were used to select for the multivariate. Final variables were selected using a stepwise
selection method with entry level = 0-20 and stay level = 0-15. Multivariate survival analysis using Cox’s regression model was estimated using 
162 patients.
fMIPI score = 0-03535 *  age + 0-6978 *  (if ECOG PS >1) + 1-367 *  log10 (LDH/ULN) + 0-9393 *  log10 (WBC per 10~6/l).
}High LDH was >3-4 pkat/l for patients aged <60 years and >3-5 pkat/l for those aged >60 years; low LDH was <1-8 pkat/l; normal was defined 
per local laboratory criteria.
§High tumour burden was defined by at least one lesion >5 cm in diameter or three lesions >3 cm in diameter by central radiology review.
^Bulky disease was defined by at least one lesion >7 cm in the longest diameter by central radiology review.
**For estimation of bone marrow involvement by local pathologist, negative was defined as having no aggregates or only a few well-circumscribed 
lymphoid aggregates, indeterminate bone marrow was defined as having an increased number/size of lymphoid aggregates without overt malig­
nancy, and positive was defined as an unequivocal malignancy.
ffNormal renal function was defined as CrCl of >60 ml/min; moderate insufficiency had CrCl >30 to <60 ml/min but not requiring dialysis; sev­
ere insufficiency had CrCl <30 ml/min. 2 patients had severe insufficiency in this study.
}}Relapse included patients with best response to last treatment of CR, unconfirmed CR, or partial response.
§§HDT was defined as SCT, hyper-CVAD (hyper fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone plus methotrexate and 
cytarabine), or R-hyper-CVAD (rituximab + Hyper CVAD).
investigator assessment. One lim itation o f  M CL-002 is that 
temsirolimus, ibrutinib, and other newer agents that are now 
available for use in M CL were not considered standard treat­
ment when recruitment in the M CL-002 study began. Thus, 
although lenalidomide was favoured over IC in the univariate 
and multivariate analyses, the results m ay have been influ­
enced by the treatment options available in the IC arm.
Several studies o f  tem sirolim us and ibrutinib have reported 
sim ilar efficacy by PFS or ORR across subgroups. Tem- 
sirolim us versus single-agent IC (primarily, gemcitabine and
fludarabine) showed consistently longer PFS across sex, perfor­
mance status, disease stage at diagnosis, bone m arrow involve­
ment and number o f  prior regimens in exploratory subgroup 
analyses o f  a phase III trial (Hess et al, 2009) and in a recent 
retrospective analysis, across MIPI risk categories (Hess et al,
2015). Subgroup analyses o f  a single-arm phase II trial o f  ibru- 
tinib in 111 patients with relapsed/refractory M CL found sim i­
lar ORRs, irrespective o f  m ultiple baseline factors, including 
tum our bulk (>5 and >10 cm  cut-offs), >2 prior treatment 
regimens and refractory disease (less than partial response to
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last prior therapy) (W ang et al, 2015). M ore recently, an open- 
label phase III study showed that ibrutinib was superior to 
tem sirolim us with regard to improvements in PFS overall and 
when broken down by subgroups (Dreyling et al, 2016).
Another lim itation o f  our analysis is that, despite the rela­
tively large size o f  the study population, M CL-002 was not 
powered to detect statistical differences in PFS between sub­
groups, and the subgroup analyses were prespecified to be 
exploratory in nature. Therefore, observed differences 
between lenalidomide and IC should not be overinterpreted. 
Similarly, the lack o f  statistical significance between lenalido- 
m ide and IC in som e subgroups should be interpreted with 
caution. W hat makes lenalidomide unique and different from 
other treatments is the longevity o f  its responses.
It is interesting to consider the factors (i.e., norm al LDH, 
no bulky disease, <3  prior antilym phom a therapies, 
> 6  m onths since last prior therapy) identified by our m ulti­
variate analysis as having a significant positive im pact on 
PFS, in addition to lenalidomide treatment. The MIPI has 
been validated and refined for previously untreated patients 
who received chemotherapy ±  rituxim ab (Hoster et al, 2008, 
2014). In our analysis, som e but not all o f  the M IPI-based 
factors were identified here as having a significant im pact on 
PFS. How these factors might help risk-stratify patients in 
the relapsed/refractory setting and with newer, m ore targeted 
agents remains to be defined in future larger analyses.
In conclusion, the prespecified subgroup and multivariate 
analyses for study M CL-002 indicate that lenalidomide 
improves PFS com pared with single-agent IC therapy in 
patients with relapsed/refractory MCL, independent o f  m ost 
patient demographic and clinical characteristics, and prior 
treatment history.
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Fig S1. Subgroup analysis o f  ORR at cycle 3 in the intent- 
to-treat population for lenalidomide versus IC-treated 
patients (investigator’s assessment; M arch 7, 2016, data cut­
off). Statistical significance for P  values o f  ORR com parisons 
was determined by W ald X 2 test (P <  0-05). IC, investiga­
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References
Avivi, I. & Goy, A. (2015) Refining the mantle cell 
lymphoma paradigm: im pact o f novel therapies
on current practice. Clinical Cancer Research, 21, 
3853-3861.
Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, 
M.A., Fisher, R.I., Connors, J.M., Lister, T.A.,
Vose, J., Grillo-Lopez, A., Hagenbeek, A., Caban- 
illas, F., Klippensten, D., Hiddemann, W., Castel- 
lino, R., Harris, N.L., Armitage, J.O., Carter, W., 
Hoppe, R. & Canellos, G.P. (1999) Report o f an
234 © 2017 The Authors. British Journa l o f  Haem atology  published by John W iley & Sons Ltd.
British Journa l o f  H aem atology, 2 018 , 180, 224-235
M CL-002 Subgroup Analysis of Lenalidomide versus IC in MCL
international workshop to standardize response 
criteria for non-Hodgkin’s lymphomas. NCI 
Sponsored International Working Group. Journal 
o f Clinical Oncology, 17, 1244-1253.
Dreyling, M., Geisler, C., Hermine, O., Kluin-Nele- 
mans, H.C., Le Gouill, S., Rule, S., Shpilberg, 
O., Walewski, J. & Ladetto, M. (2014) Newly 
diagnosed and relapsed mantle cell lymphoma: 
ESM O Clinical Practice Guidelines for diagnosis, 
treatment and follow-up. Annals o f Oncology, 25 
(Suppl. 3), iii83-iii92.
Dreyling, M ., Jurczak, W., Jerkeman, M ., Silva, 
R.S., Rusconi, C., Trneny, M ., Offner, F., 
Caballero, D., Joao, C., W itzens-Harig, M., 
Hess, G., Bence-Bruckler, I., Cho, S.G., 
Bothos, J., Goldberg, J.D., Enny, C., Traina,
5., Balasubram anian, S., Bandyopadhyay, N., 
Sun, S., Vermeulen, J., Rizo, A. & Rule, S. 
(2016) Ibrutinib versus tem sirolim us in 
patients with relapsed or refractory mantle­
cell lym phom a: an international, random ised, 
open-label, phase 3 study. Lancet, 387, 770­
778.
Goy, A., Sinha, R., Williams, M.E., Kalayoglu Besi- 
sik, S., Drach, J., Ramchandren, R., Zhang, L., 
Cicero, S., Fu, T. & Witzig, T.E. (2013) Single­
agent lenalidomide in patients with mantle-cell 
lymphoma who relapsed or progressed after or 
were refractory to bortezomib: phase II MCL- 
001 (EMERGE) study. Journal o f Clinical Oncol­
ogy, 31, 3688-3695.
Goy, A., Kalayoglu Besisik, S., Drach, J., Ramchan- 
dren, R., Robertson, M.J., Avivi, I., Rowe, J.M., 
Herbrecht, R., Van Hoof, A., Zhang, L., Cicero,
5., Fu, T. & Witzig, T. (2015) Longer-term fol­
low-up and outcome by tum our cell prolifera­
tion rate (Ki-67) in patients with relapsed/ 
refractory mantle cell lymphoma treated with 
lenalidomide on MCL-001(EMERGE) pivotal
trial. British Journal o f Haematology, 170, 496­
503.
Gribben, J.G., Fowler, N. & Morschhauser, F. 
(2015) Mechanisms o f  action o f lenalidomide in 
B-cell non-Hodgkin lymphoma. Journal o f Clini­
cal Oncology, 33, 2803-2811.
Habermann, T.M., Lossos, I.S., Justice, G., Vose, 
J.M., Wiernik, P.H., McBride, K., Wride, K., 
Ervin-Haynes, A., Takeshita, K., Pietronigro, D., 
Zeldis, J.B. & Tuscano, J.M. (2009) Lenalido- 
mide oral monotherapy produces a high 
response rate in patients with relapsed or refrac­
tory mantle cell lymphoma. British Journal of 
Haematology, 145, 344-349.
Hess, G., Herbrecht, R., Romaguera, J., Verhoef,
G., Crump, M., Gisselbrecht, C., Laurell, A., Off- 
ner, F., Strahs, A., Berkenblit, A., Hanushevsky, 
O., Clancy, J., Hewes, B., Moore, L. & Coiffier,
B. (2009) Phase III study to evaluate tem- 
sirolimus compared with investigator’s choice 
therapy for the treatment o f relapsed or refrac­
tory mantle cell lymphoma. Journal o f Clinical 
Oncology, 27, 3822-3829.
Hess, G., Coiffier, B., Crump, M., Gisselbrecht, C., 
Offner, F., Romaguera, J., Kang, L. & Moran, 
P.J. (2015) Effect o f prognostic classification on 
temsirolimus efficacy and safety in patients with 
relapsed or refractory mantle cell lymphoma: a 
retrospective analysis. Experimental Hematology 
& Oncology, 4, 11.
Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht,
C., van Hoof, A., Kluin-Nelemans, H.C., Pfre- 
undschuh, M., Reiser, M., Metzner, B., Einsele,
H., Peter, N., Jung, W., Wormann, B., Ludwig, 
W.D., Duhrsen, U., Eimermacher, H., Wandt, 
H., Hasford, J., Hiddemann, W. & Unterhalt, 
M. (2008) A new prognostic index (MIPI) for 
patients with advanced-stage mantle cell lym­
phoma. Blood, 111, 558-565.
Hoster, E., Klapper, W., Hermine, O., Kluin-Nele- 
mans, H.C., Walewski, J., van Hoof, A., Trneny, 
M., Geisler, C.H., Di Raimondo, F., Szymczyk, 
M., Stilgenbauer, S., Thieblemont, C., Hallek, 
M., Forstpointner, R., Pott, C., Ribrag, V., 
Doorduijn, J., Hiddemann, W., Dreyling, M.H. 
& Unterhalt, M. (2014) Confirmation o f the 
mantle-cell lymphoma international prognostic 
index in randomized trials o f the European 
mantle-cell lymphom a network. Journal o f Clini­
cal Oncology, 32, 1338-1346.
Trneny, M., Lamy, T., Walewski, J., Belada, D., 
Mayer, J., Radford, J., Jurczak, W., Morschhauser, 
F., Alexeeva, J., Rule, S., Afanasyev, B., Kaplanov, 
K., Thyss, A., Kuzmin, A., Voloshin, S., Kulicz- 
kowski, K., Giza, A., Milpied, N., Stelitano, C., 
Marks, R., Trumper, L., Biyukov, T., Patturajan, 
M., Bravo, M.L. & Arcaini, L. (2016) Lenalido- 
mide versus investigator’s choice in relapsed or 
refractory mantle cell lymphoma (M CL-002; 
SPRINT): a phase 2, randomised, multicentre 
trial. The Lancet. Oncology, 17,319-331.
Wang, M.L., Blum, K.A., Martin, P., Goy, A., 
Auer, R., Kahl, B.S., Jurczak, W., Advani, R.H., 
Romaguera, J.E., Williams, M.E., Barrientos, 
J.C., Chmielowska, E., Radford, J., Stilgenbauer,
S., Dreyling, M., Jedrzejczak, W.W., Johnson, P., 
Spurgeon, S.E., Zhang, L., Baher, L., Cheng, M., 
Lee, D., Beaupre, D.M. & Rule, S. (2015) Long­
term follow-up o f M CL patients treated with 
single-agent ibrutinib: updated safety and effi­
cacy results. Blood, 126, 739-745.
Zinzani, P.L., Vose, J.M., Czuczman, M.S., Reeder,
C.B., Haioun, C., Polikoff, J., Tilly, H., Zhang, 
L., Prandi, K., Li, J. & Witzig, T.E. (2013) Long­
term follow-up o f lenalidomide in relapsed/re­
fractory mantle cell lymphoma: subset analysis 
o f the NHL-003 study. Annals o f Oncology, 24, 
2892-2897.
© 2017 The Authors. British Journa l o f  H aem atology  published by John W iley & Sons Ltd.
British Journal o f  H aem atology, 2018 , 180, 224 -2 3 5
235
